December 05, 2024

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation Entered into Research Collaboration with Dewpoint to Advance Small Molecule Condensate Modulator for ALS

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura, hereinafter, "MTPC") of the Mitsubishi Chemical Group have entered into a strategic research collaboration with Dewpoint Therapeutics, Inc. (Head Office: Boston, Massachusetts; CEO: Ameet Nathwani, "Dewpoint ") to advance Dewpoint's TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1st, 2024.

Under the terms of the agreement, MTPC will pay Dewpoint an upfront payment. Upon reaching certain pre-specified milestones, MTPC will have the exclusive option to license the program and assume responsibility for global clinical development and commercialization.

MTPC, which positions central nervous system diseases as one of its key areas, is contributing to people living with ALS worldwide as a leading company in the treatment of ALS by delivering RADICAVA ORS® and RADICAVA®.

MTPC Group will continue working to provide new treatment options in the field of ALS and the central nervous system.

Contact:
Mitsubishi Tanabe Pharma Corporation
Pharma Business Strategy Division
PR Department
+81-6-6205-5119

■ About Dewpoint Therapeutics

Dewpoint is the leading biotech company in the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed 'undruggable,' opening unexplored avenues to identify hundreds of novel therapeutic targets. Funded by a syndicate of top VCs, Dewpoint's proprietary AI-powered platform is built to produce a pipeline of first-in-class drugs spanning therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with other pharmaceutical companies, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on X and LinkedIn.

■ About Condensate

Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate biomolecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiovascular, and neurological disorders. Condensate modulators (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets.